Cyclo Therapeutics, Inc.
CYTHDelisted Mar 26, 2025- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0000922247
Cyclo Therapeutics, Inc. was delisted on Mar 26, 2025; its insiders filed their last Form 4 on Mar 3, 2025; 22 institutions reported holding it in 13F filings for Q4 2024, worth $1.33M in total; no superinvestor held it.
13F holders, Q3 2021
Institutional positions in Cyclo Therapeutics, Inc. as of Sep 30, 2021. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 13
- +1 vs. Q2 2021
- Shares held
- 331.0K
- +67.3K (+25.5%) vs. Q2 2021
- Total value
- $2.23M
- −$463.0K (−17.2%) vs. Q2 2021
- New holders
- 2
- 5 more added
- Sold out
- 1
- 3 more reduced
Compare with Q2 2021: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting CYTH on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 0 | $0 |
| Q1 2026 | 0 | $0 |
| Q4 2025 | 0 | $0 |
| Q3 2025 | 0 | $0 |
| Q2 2025 | 0 | $0 |
| Q1 2025 | 0 | $0 |
| Q4 2024 | 22 | $1.33M |
| Q3 2024 | 19 | $1.80M |
| Q2 2024 | 22 | $2.84M |
| Q1 2024 | 22 | $3.01M |
| Q4 2023 | 23 | $2.06M |
| Q3 2023 | 17 | $682.7K |
| Q2 2023 | 14 | $725.2K |
| Q1 2023 | 16 | $820.2K |
| Q4 2022 | 15 | $1.83M |
| Q3 2022 | 12 | $768.0K |
| Q2 2022 | 13 | $794.0K |
| Q1 2022 | 13 | $1.38M |
| Q4 2021 | 15 | $1.71M |
| Q3 2021 | 13 | $2.23M |
| Q2 2021 | 12 | $2.70M |
| Q1 2021 | 9 | $585.0K |
Institutions, Q3 2021
Shares, value and share of portfolio for each institution holding Cyclo Therapeutics, Inc.; share changes are against Q2 2021.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Wells Fargo & Company | 35 | $0 | 0.00% | −1−2.8% | Reduced |
| Captrust Financial Advisors | 100 | $1.00K | 0.00% | 00.0% | Unchanged |
| Morgan Stanley | 503 | $3.00K | 0.00% | −900−64.1% | Reduced |
| Royal Bank of Canada | 746 | $5.00K | 0.00% | 00.0% | Unchanged |
| Tower Research Capital LLC (TRC) | 1,154 | $8.00K | 0.00% | +589+104.2% | Added |
| Renaissance Technologies LLC | 10,482 | $71.0K | 0.00% | +10,482 | New |
| Two Sigma Advisers, LP | 12,200 | $82.0K | 0.00% | +12,200 | New |
| BlackRock Inc. | 13,134 | $88.0K | 0.00% | +2,290+21.1% | Added |
| State Street Corp | 29,600 | $200.0K | 0.00% | −15,100−33.8% | Reduced |
| UBS Group AG | 39,914 | $269.0K | 0.00% | +28,820+259.8% | Added |
| Geode Capital Management, LLC | 51,454 | $347.0K | 0.00% | +8,877+20.8% | Added |
| Vanguard Group Inc | 171,681 | $1.16M | 0.00% | +20,141+13.3% | Added |
| IFP Advisors, Inc | 13 | – | – | 00.0% | Unchanged |
| Advisory Services Network, LLC | 0 | $0 | 0.00% | −100−100.0% | Sold out |